| 8:30 | WELCOME SESSION AND SESSION 1: [SURGICAL] | Lars Lund Bradley Leibovich | Region Syddanmark Mayo Clinic |
| Treatment Debate Localized Disease: A: Introduction of Active Surveillance vs. Therapy | Sarah Psutka | UW | |
| Treatment Debate Localized Disease: B: Surgical options for localized disease | Pernilla Sundqvist | Region Örebro | |
| The risks and benefits of neoadjuvant therapy in locally advanced RCC | Grant Stewart | University of Cambridge | |
| Results from Adjuvant Trials: how to select patients and therapies | Viktor Grünwald | Universität Essen | |
| Surgery in primary metastatic disease: who, how, when? | Arnaud Mejean | Hôpital Européen Georges-Pompidou | |
| 10:15 | SESSION 2: [PATHOLOGY] | Samra Turajlic Elizabeth (Lisa) Henske | The Institute of Cancer Research Brigham & Women’s, Harvard Medical School |
| WHO pathological classification: Present and Future | Ferran Algaba Arrea | Fundació Puigvert | |
| AI/Digital Pathology | Payal Kapur | UT Southwestern | |
| Epigenetic regulation of oncogenic signaling in RCC | Jessica Downs | The Institute of Cancer Research | |
| Developing accurate mouse models of ccRCC | Ari Hakimi | Memorial Sloan Kettering Cancer Center | |
| Understanding non-clear cell molecular pathology | Elizabeth (Lisa) Henske | Brigham & Women’s, Harvard Medical School | |
| Sarcomatoid and Rhadoid Subtypes and clinical implications | Bradley Leibovich | Mayo Clinic | |
| 11:30 | Keynote I | Robert Jones | Beatson West of Scotland Cancer Centre |
| 11:45 | SESSION 3: CARING FOR THE WHOLE PATIENT: NON CLINICAL CONSIDERATIONS | Michael Staehler Cristina Suárez | Ludwig-Maximilians University of Munich Vall d’Hebron Hospital Universitari |
| Living with RCC – long term survival and frustration | Theresa Junker | Region Syddanmark | |
| Supplements and Concomitant Drugs – Interactions, Efficacy | Dora Niedersüß-Beke | Wilhelminenspital Vienna | |
| Patients trust in care | Dena Battle | KCCure | |
| Quality of life – what is that and how can we optimize it? | David Cella | Northwestern Medicine-Feinberg School of Medicine | |
| Rare subtypes – a patients tale | Per Larsen | Retired chief of police – patient | |
| 12:45 | POSTERS AND LUNCH | ||
| 13:00 | Industry Session | ||
| 14:15 | SESSION 4: ORAL ABSTRACTS | Gabriel Malouf Lars Lund | Institut de Cancérologie de Strasbourg & IGBMC Region Syddanmark |
| 15:30 | SESSION 5: TREATMENT DEBATES FIRST LINE THERAPY | Viktor Grünwald Lisa Pickering | Universitätsklinikum Essen Royal Marsden NHS Foundation Trust |
| IO-TKI 2blets vs IO-TKI 3plets Debate (3plet presenter) | Tian Zhang | UTSW | |
| IO-TKI 2blets vs IO-TKI 3plets Debate (2blet presenter) | Laurence Albiges | Gustave Roussy Cancer Campus | |
| IO-IO Debate | Mike Atkins | Georgetown-Lombardi Comprehesive Cancer Center | |
| Illustrative Clinical scenarios of ea above (wrap up info) | Lisa Pickering | Royal Marsden NHS Foundation Trust | |
| Optimal toxicity management in an era of increasing doublet and triplet therapies. | Kate Young | Royal Marsden NHS Foundation Trust | |
| 16:30 | KEYNOTE II: AWARDS | ||
| 16:55 | WOMEN IN RCC (SPONSORED SESSION) | Laurence Albiges Lisa Pickering | Gustave Roussy Cancer Campus Royal Marsden NHS Foundation Trust |
| 17:55 | RECEPTION | ||
| 18:15 | Poster Walk | Ignacio Duran Tim O’Brien | Universidad Tecnológica Metropolitana Guy’s and St Thomas’ NHS Foundation Trust |
| 8:30 | WELCOME SESSION AND SESSION 6: KCA UPDATES | Dan George Dora Niedersüß-Beke | Duke University Medical Center Wilhelminenspital Vienna |
| KCA Updates | |||
| KEYNOTE III (Award Winners) | |||
| 9:00 | SESSION 7: BEYOND SECOND LINE THERAPY | Laurence Albiges Dan George | Gustave Roussy Cancer Campus Duke University Medical Center |
| Criteria to select further lines of therapies after IO-IO 1st line | Ulka Vaishampayan | University of Michigan | |
| How to select further line therapies and why after IO-TKI 1st line | Ignacio Duran | Universidad Tecnológica Metropolitana | |
| Integrating predictive biomarkers into therapy selection | Gabriel Malouf | Institut de Cancérologie de Strasbourg & IGBMC | |
| Oxford debate on optimizing later line therapy selection | Camillo Porta | San Matteo University Hospital | |
| 10:05 | SESSION 8 – MANAGEMENT OF RCC | Sylvie Negrier Ulka Vaishampayan | UNICANCER University of Michigan |
| Future radiotherapy options | Raquib Hannan | UT Southwestern Medical Center | |
| Staging and Restaging of RCC and mRCC | Daniel Heng | Tom Baker Cancer Center | |
| Modern PET Imaging | Lena Unterrainer | Resident, LMU Munich | |
| 11:15 | SESSION 9 – NON CLEAR CELL RCC | Cristina Suárez Mike Atkins | Vall d’Hebron Hospital Universitari Georgetown-Lombardi Comprehesive Cancer Center |
| Papillary RCC | Manuela Schmidinger | AKH Wien | |
| CDC, RMC | Giuseppe Procopio | Istituto Nazionale dei Tumori | |
| Treatment of molecularly defined metastatic RCC | Stéphane Oudard | AP-HP. Centre – Université de Paris – HEGP Hôpital Européen Georges Pompidou | |
| Role of IO in non-clear RCC | Nizar Tannir | UT MD Anderson Cancer Center | |
| 12:15 | Lunch and Posters | ||
| 12:30 | Industry Session | ||
| 13:45 | SESSION 10: BASIC SCIENCE INTEGRATED INTO THERAPEUTIC MANAGEMENT | Annika Fendler Elizabeth (Lisa) Henske | Crick Institue Brigham & Women’s, Harvard Medical School |
| TLS and B-cell responses in RCC | Florent Petitprez | The University of Edinburgh | |
| Circulating T cell activation as predictor of therapy response | Haydn Kissick | Emory University | |
| Patient-derived organotypic cultures predict immunotherapy responses | Marieta Toma | University Hospital Bonn | |
| Heterogeneity in Transcriptomics | Annika Fendler | Crick Institute | |
| Optimizing clinical trial designs by integrating tissue derived markers | Samra Turajlic | The Institute of Canceer Research | |
| 14:45 | SESSION 11: SPECIAL TOPICS | Sylvie Negrier | UNICANCER |
| Gut microbiome to influence IO response | Nazli Dizman | Yale University | |
| HIF2a in VHL and beyond | Tian Zhang | UT Southwest | |
| Novel therapeutics *except HiF2a | Thomas Powles | NHS Barts Health | |
| Therapy of patients with and of brain metastases | Sylvie Negrier | UNICANCER | |
| 15:40 | POSTER AWARD PRESENTATION | Lisa Pickering Lars Lund | Royal Marsden NHS Foundation Trust Region Syddanmark |
| 15:50 | WOODFIRE | Michael Staehler | Ludwig-Maximilians University of Munich |
| Bradley Leibovich | Mayo Clinic | ||
| Ulka Vaishampayan | University of Michigan | ||
| Arnaud Mejean | Hôpital Européen Georges-Pompidou | ||
| Thomas Powles | NHS Barts Health | ||
| 16:50 | SESSION CLOSING | Michael Staehler | Ludwig-Maximilians University of Munich |
| Gabriel Malouf | Institut de Cancérologie de Strasbourg & IGBMC | ||